Journal of Digestive Cancer Research

Korean Society of Gastrointestinal Cancer Research (대한소화기암연구학회)
권호 표지

Current and Future Role of the Gastroenterologist in GI Cancer Management

  • John M. Carethers (Division of Gastroenterology, Department of Internal Medicine, University of Michigan)
  • Received : 2013.09.04
  • Accepted : 2013.10.24
  • Published : 2013.11.30
Download PDF
⟨ Previous Next ⟩

Abstract

With advances in technology, advances in the understanding of biology of cancer, and the advent of improved and novel therapies, the role of the gastroenterologist has been modified greatly over the past 2 decades, and continues to be shaped by the knowledge, skill, and opportunity to capitalize on the unique position that gastroenterologists hold in the patient care continuum. The gastroenterologist is evolving from a "pure" diagnostician to an endoscopic surgeon, a geneticist, a nutritionist, an immunologist and chemotherapist, and palliative care physician.

Keywords

Acknowledgement

This work was supported by the United States Public Health Service(DK067287 and CA162147). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. This manuscript was presented at least in part at the 2013 International Symposium of the Korean Society of Gastrointestinal Cancer.

References

  1. Wang KK, Wongkeesong M, Buttar NS. American Gastroenterological Association medical position statement: role of the gastroenterologist in the management of esophageal carcinoma. Gastroenterology 2005; 128:1468-1470.
  2. Winawer SJ, Pasricha PJ, Schmeigel W, Sinicrope FA, Sung J, Seufferlein T, Kassem AM, Malekzadeh R, Kurtz RC, Classen M, Tytgat GN. The future role of the gastroenterologist in digestive oncology: an international perspective. Gastroenterology 2011;141:e13-e21.
  3. Terdiman JP. Oncology training for the gastroenterologist: a test-case for subspecialization in gastroenterology? Gastroenterology 2008;135:1028-1031.
  4. Cancer Genome Atlas Nework Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012;487:330-337.
  5. Carethers JM. Proteomics, genomics and molecular biology in the personalized treatment of colorectal cancer. J Gastrointest Surg 2012;16:1648-1650.
  6. Carethers JM, Smith EJ, Behling CA, Nguyen L, Tajima A, Doctolero RT, Cabrera BI, Goel A, Arnold CA, Miyai K, Boland CR Use of 5-fluorouradl and survival in patients with microsatellite unstable colorectal cancer. Gastroenterology 2004;126:394-401.
  7. Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M, Imamura Y, Qian ZR, Baba Y, Shima K, Sun R, Nosho K, Meyerhardt JA, Giovannucci E, Fuchs CS, Chan AT, Ogino S. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 2012;367:1596-606.
  8. Boland CR, Jung B, Carethers JM. Cancer of the colon and gastrointestinal tract. Chapter 74. In, Emery and Rimoin's Principles and Practice of Medical Genetics, 6th Ed, edited by Pyeritz RE, Rimoin DL, and Korf BR, Churchill Livingstone, Edinburgh, 2013.
  9. Carethers JM. The gastroenterologist and chemotherapy for digestive cancers: a potential role in central management of the patient. AGA Perspectives 2006;2:4-14.